We’re thrilled to announce that Mtech Access will be exhibiting at the ISPOR conference May 5–8 in Atlanta, Georgia, USA!
As regular attendees of ISPOR Europe, we’re excited to be attending this global conference for the first time, where we can meet some of our clients on their home turf. Speak to our team at ISPOR to learn more about how we partner with Pharma and Medtech leaders to drive optimal global commercialisation. Our programmes of support include:
- Evidence, pricing and access strategy
- Development of a robust evidence base
- National, regional, and local reimbursement, and formulary inclusion
- Communication of value to clinical and financial decision-makers
Our virtual booth for ISPOR 2024 is now live.
Let’s arrange a time to meet
We are eager to make new connections, reconnect with old friends, and forge lasting partnerships during this exciting event. You’ll find us at booth 125, near theatre 2.
With ISPOR offering such a wide variety of sessions and networking opportunities, we know many ISPOR attendees will want to plan their schedule ahead of time. You wouldn’t want to miss anything, after all! So, if you’re one of the planners, we’d love to arrange a time to meet in advance.
Book in a meeting now using the form and we’ll:
- Fit in around your ISPOR schedule
- Ensure you have dedicated time with relevant experts who can help with your biggest challenges and opportunities
- Prepare a structured agenda for our conversation targeting your submitted areas of focus
- Come with resources and insights relevant to your markets and disease areas
- Gift you a voucher for 1 hour of free consultancy with our expert team, redeemable after the conference
Let’s meet at ISPOR
Complete the form to arrange a time to meet our team at ISPOR:
Who’s attending from Mtech Access?
Discover why we’re different at ISPOR
“Mtech Access challenged us to do something a little bit different” – Health Economics Lead, Top 5 Pharma Company.
We’re excited to show you how we do things differently at Mtech Access. Our clients benefit from collaborative, expert-driven, solutions-focused partnerships. We challenge and inspire them to achieve the best results, applying innovation and agility to everything we do.
Our centres of excellence:
- Strategic consulting
- Expert opinion and insights
- Evidence synthesis
- Economic modelling, data analysis, and statistics
- Value propositions, storytelling, and positioning
- Cutting-edge digital and design
We have extensive experience in all therapy areas and deep expertise in rare disease, oncology, respiratory, diabetes and obesity, neurology, and immunology.
Check out the following case studies showcasing our work with global and US market teams:
View Case StudyDelivering on global market access strategy, evidence generation, and communication objectives
View Case StudyExploring the US market landscape and developing strategy for a digital health technology
View Case StudyBuilding a budget impact model for AMCP submission in the US
View Case StudyGaining global payer insights to inform clinical trial design, price and market access strategy
View Case StudyResearching market access pathways, reimbursement requirements and implications of orphan drug designation for a rare disease product
View Case StudyReviewing HTA decisions in key markets across the globe
View Case StudyCommunicating value with a suite of visually impactful materials connected via a digital platform
View Case StudyExploring funding and reimbursement routes for digital health technologies across EU4, UK and US
View Case StudyChallenging European policy proposals with an evidence-driven submission on behalf of a cross-industry consortium
Key reads and insights ahead of ISPOR
What role does ICER play in US market access?
We delve into ICER’s influence on drug pricing and access in the US. We also explore the importance of maximising engagement with ICER for favourable pricing and access outcomes…
Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics
We bring together specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024-25. Jump in, as our experts give their hot-take on each trend, sharing their perspectives on what’s happening in these areas…
EThe role of economic evaluation in US healthcare
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US and highlight important considerations for companies seeking to infiltrate this key market….
Free guide to market access and reimbursement in key European markets
Request your copy of our popular introductory guide: ‘Market access and reimbursement in key European markets’…
AMCP dossier planning for US market access and reimbursement
What is an AMCP dossier and how are they used in US market access? Drawing on their extensive experience compiling AMCP dossiers, here, our global market access experts explain when, why and how…
EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?…
6 questions to ask when adapting global market access materials for local markets
How can you ensure that the market access materials, value proposition and evidence developed by global teams, will resonate for your local audience?…
Setting your product up for success – commercialisation strategy for the US market
How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice…
